

(19)



(11)

EP 3 881 680 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 1 (W1 B1)

Corrections, see

Bibliography INID code(s) 84

(48) Corrigendum issued on:

26.02.2025 Bulletin 2025/09

(45) Date of publication and mention
of the grant of the patent:

15.01.2025 Bulletin 2025/03

(21) Application number: **21157228.4**

(22) Date of filing: **30.10.2015**

(51) International Patent Classification (IPC):

A01N 63/00 ^(2020.01) **C12N 1/20** ^(2006.01)
A61K 31/733 ^(2006.01) **A61K 35/74** ^(2015.01)
A61K 45/06 ^(2006.01) **A23L 33/135** ^(2016.01)
A61K 35/741 ^(2015.01) **A61K 35/00** ^(2006.01)
A61P 3/00 ^(2006.01) **A61P 3/04** ^(2006.01)
A61P 3/10 ^(2006.01)

(52) Cooperative Patent Classification (CPC):

(C-Sets available)

A23L 33/135; A61K 31/733; A61K 35/74;
A61K 35/741; A61K 45/06; A61P 3/00; A61P 3/04;
A61P 3/10; C12N 1/20; A23V 2002/00;
A61K 2035/115; G01N 2333/605; G01N 2800/04

(Cont.)

(54) **METHODS AND COMPOSITIONS RELATING TO MICROBIAL TREATMENT**

VERFAHREN UND ZUSAMMENSETZUNGEN IM ZUSAMMENHANG MIT MIKROBIELLER
BEHANDLUNG VON STÖRUNGEN

PROCÉDÉS ET COMPOSITIONS SE RAPPORTANT À UN TRAITEMENT MICROBIEN DE
TROUBLES

(84) Designated Contracting States:

AL AT BE BG CH CY CZ DE DK EE ES FI FR GR
HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL
PT RO RS SE SI SK SM TR

(30) Priority: **31.10.2014 US 201462073912 P**

(43) Date of publication of application:

22.09.2021 Bulletin 2021/38

(60) Divisional application:

24218291.3

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:

15853671.4 / 3 212 001

(73) Proprietor: **Pendulum Therapeutics, Inc.**

San Francisco, CA 94107 (US)

(72) Inventors:

- **CUTCLIFFE, Colleen**
Menlo Park, CA California 94025 (US)
- **EID, John S.**
San Francisco, CA California 94110 (US)

• **BULLARD, James H.**

San Francisco, CA California 94107 (US)

• **SCHICKLBERGER, Marcus F.**

Richmond, CA California 94804 (US)

(74) Representative: **Avidity IP**

Broers Building

Hauser Forum

21 JJ Thomson Avenue

Cambridge CB3 0FA (GB)

(56) References cited:

WO-A1-2014/011233 WO-A1-2014/152338

WO-A2-2014/145958 JP-A- 2007 031 291

US-A- 5 143 845 US-A1- 2009 010 891

US-A1- 2009 010 892 US-A1- 2013 224 155

• **MEKKES M C ET AL: "The development of
probiotic treatment in obesity: a review",**

BENEFICIAL MICR, WAGENINGEN ACADEMIC

PUBLISHERS, NL, vol. 5, no. 1, 1 March 2014

(2014-03-01), pages 19 - 28, XP009181740, ISSN:

1876-2883, DOI: 10.3920/BM2012.0069

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 881 680 B8

- **FALONY G ET AL:** "Cross-feeding between *Bifidobacterium longum* BB536 and acetate-converting, butyrate-producing colon bacteria during growth on oligofructose", **APPLIED AND ENVIRONMENTAL MICROBIOLOGY** DECEMBER 2006 **AMERICAN SOCIETY FOR MICROBIOLOGY** US, vol. 72, no. 12, December 2006 (2006-12-01), pages 7835 - 7841, XP028249378, DOI: 10.1128/AEM.01296-06
- **DATABASE GNPD [online] MINTEL;** February 2015 (2015-02-01), **PHARMXCROSS:** "Triple Premium Alive Probiotics", XP002779023, Database accession no. 2898253
- **PETRA LOUIS ET AL:** "Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine", **FEMS MICROBIOLOGY LETTERS**, vol. 294, no. 1, 1 May 2009 (2009-05-01), pages 1 - 8, XP055397860, ISSN: 0378-1097, DOI: 10.1111/j.1574-6968.2009.01514.x
- **M. VITAL ET AL:** "Revealing the Bacterial Butyrate Synthesis Pathways by Analyzing (Meta)genomic Data", **MBIO**, vol. 5, no. 2, 22 April 2014 (2014-04-22), US, pages 1 - 11, XP055195014, ISSN: 2150-7511, DOI: 10.1128/mBio.00889-14
- **ALESSANDRA PUDDU ET AL:** "Evidence for the Gut Microbiota Short-Chain Fatty Acids as Key Pathophysiological Molecules Improving Diabetes", **MEDIATORS OF INFLAMMATION.**, vol. 2014, 1 January 2014 (2014-01-01), GB, pages 1 - 9, XP055397861, ISSN: 0962-9351, DOI: 10.1155/2014/162021

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

(52) Cooperative Patent Classification (CPC): (Cont.)

C-Sets

A61K 31/733, A61K 2300/00;

A23V 2002/00, A23V 2200/3202, A23V 2200/3204,

A23V 2200/328, A23V 2200/332